U.S. and European organ-on-a-chip specialty biotechnology companies are driving development of organ-on-a-chip technologies, fueled by the U.S. FDA’s decision to phase out animal testing for investigational new drugs.
U.S. and European organ-on-a-chip specialty biotechnology companies are driving development of organ-on-a-chip technologies, fueled by the U.S. FDA’s decision to phase out animal testing for investigational new drugs.
The preBötzinger complex (preBötC) appears to play a relevant role in opiate-induced respiratory depression, as suggested by studies in animal models. However, limited research concerning preBötC physiology in humans has been conducted, and no human in vitro models of the preBötC exist.
CN Bio Ltd. launched the Physiomimix single-organ higher throughput system commercially in hopes it will foster the adoption of microphysiological systems which increase productivity, improve data quality and offer cost-effective solutions for drug discovery.
The use of organoids in preclinical research has reached a tipping point, with U.S. FDA approval of the first drug to enter clinical trials on the basis of efficacy data derived only from these advanced cell models.
Hesperos Inc.'s Human-on-a-Chip in vitro system demonstrated two types of responses of the immune system in a study conducted with Hoffman-La Roche Pharmaceuticals and the University of Central Florida.
Hesperos Inc.'s human-on-a-chip in vitro model for the first time successfully predicted human response to two drugs. The multi-organ model provided new insight into the drugs' cardiotoxic effects in a study published in Nature Scientific Reports. The Orlando, Fla.-based company also recently demonstrated that its model could simultaneously measure cancer drug efficacy and off-target toxicity without animal models or human testing.
